Schrödinger (SDGR) has been back in focus after shareholders approved an amendment to the 2022 Equity Incentive Plan and the company reiterated guidance tied to its hosted software transition and emerging AI co scientist, Bunsen.

Those governance decisions and the rollout of Schrödinger’s hosted software and AI co scientist arrive after a 90 day share price return of 38.36%, alongside a 1 year total shareholder return decline of 25.18% and a 5 year total shareholder return decline of 79.97%. This combination suggests that recent momentum has picked up while longer term performance remains weak.

If you are comparing Schrödinger with other companies using AI in healthcare, it is worth scanning the market through the 38 healthcare AI stocks

With Schrödinger trading at US$15.33, carrying an intrinsic value estimate at a 52.82% discount and sitting 36.17% below the average analyst target, investors are left with a key question: is there real upside here, or is the market already pricing in the company’s next phase of growth?

Most Popular Schrödinger Narrative: 26.6% Undervalued

With Schrödinger last closing at $15.33 against a narrative fair value of $20.88, the current setup hinges on how its software and pipeline story plays out over time.

Strong pipeline advancement and early clinical success, such as positive Phase I data for SGR-1505, positions the company to secure additional milestone payments, royalties, and out-licensing deals, creating potential for substantial long-term revenue growth and more predictable future cash flows.

Curious what sits behind that confidence in Schrödinger's future cash flows? The most followed narrative leans heavily on modeled revenue growth, margin uplift, and a premium future earnings multiple to arrive at that fair value path.

Result: Fair Value of $20.88 (UNDERVALUED)

However, Schrödinger’s story could be knocked off course if software growth leans too heavily on existing customers or if milestone and royalty revenue remains uneven.

Another View on Schrödinger’s Valuation

The first valuation lens suggests Schrödinger is trading 52.8% below an estimated fair value of $32.49 using our DCF model, which points to undervaluation. A contrasting lens using the P/S ratio paints a different picture, with the stock at 4.5x sales versus 2.0x for the US Healthcare Services industry and a fair ratio of 2.1x. That gap implies investors are already paying a premium for future growth expectations, so the real question is which story you trust more.

Next Steps

With sentiment clearly split between Schrödinger’s potential rewards and the risks flagged in the data, it can be helpful to move quickly, review the details for yourself, and then weigh both sides by checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Schrödinger?

Schrödinger might be on your radar, but you will miss plenty of other opportunities if you stop here, so keep broadening your watchlist with focused stock ideas.

• Target dependable income by reviewing companies in the 7 dividend fortresses that may suit investors who prioritise yield and consistency.
• Spot potential value opportunities early by scanning the screener containing 18 high quality undiscovered gems before they attract wider market attention.
• Strengthen your downside protection by focusing on companies in the 69 resilient stocks with low risk scores that align with a more conservative approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.